Extended surveillance to assess safety of 9-valent human papillomavirus vaccine

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine

The safety of 9-valent HPV vaccine (9vHPV) has been established with regard to common and uncommon adverse events. However, investigation of rare and severe adverse events requires extended study periods to capture rare outcomes. This observational cohort study investigated the occurrence of three r...

Full description

Bibliographic Details
Main Authors: Maria E. Sundaram, Burney A. Kieke, Kayla E. Hanson, Edward A. Belongia, Eric S. Weintraub, Matthew F. Daley, Rulin C. Hechter, Nicola P. Klein, Edwin M. Lewis, Allison L. Naleway, Jennifer C. Nelson, James G. Donahue
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
human papillomavirus vaccine
vaccine safety
guillain-barré syndrome
chronic inflammatory demyelinating polyneuropathy
stroke
Online Access:http://dx.doi.org/10.1080/21645515.2022.2159215

Internet

http://dx.doi.org/10.1080/21645515.2022.2159215

Similar Items